NCT03370887 - AZD8601 Study in CABG Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Heart Failure

Interventions

DRUG

AZD8601

AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion

DRUG

Placebo

Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion

Trial Locations (10)

20520

Research Site, Turku

33520

Research Site, Tampere

70210

Research Site, Kuopio

80363

Research Site, München

81675

Research Site, München

06510

Research Site, New Haven

1081 HV

Research Site, Amsterdam

9713 GZ

Research Site, Groningen

413 45

Research Site, Gothenburg

751 85

Research Site, Uppsala